在患者中探索补充疗法使用和药物坚持的关系
Siti Nor Aqilah Mohd Noor1, Nurul Afiedia Roslim2, Shazia Jamshed3
1Faculty of Pharmacy, Universiti Sultan Zainal Abidin (UniSZA), Kampus Besut, Besut, Malaysia.
Journal of pharmaceutical policy and practice
|August 7, 2025
概括
补充和替代疗法 (CAT) 在患者中很常见,但它们的使用不会影响对抗药物 (AED) 的坚持. 为了安全,协调的治疗,需要进一步的研究.
科学领域:
- 神经学 神经学
- 综合医学是一个整体的医学.
- 公共卫生 公共卫生
背景情况:
- 补充和替代疗法 (CAT) 在患者中很普遍.
- 在PWE中,CATs对抗药物 (AED) 坚持的影响尚不清楚.
- 这项研究调查了CAT的使用,知识,态度,做法以及它们对PWE中AED坚持的影响.
研究的目的:
- 评估患者对补充疗法和替代疗法 (CAT) 的知识,态度和实践 (KAP).
- 评估CAT使用对PWE中抗药物 (AED) 坚持的影响.
主要方法:
- 一项涉及193名在半岛马来西亚患者 (PWE) 的横截面研究.
- 通过面对面调查问卷收集的数据评估了CAT的KAP和药物坚持 (MALMAS).
- 使用描述性统计和非参数测试,使用SPSS版本 26.0.0.
主要成果:
- 近60%的PWE使用CAT,主要是祈祷和按摩,通常是由于文化信仰和感知到的好处.
- 观察到对CAT的适度知识,中立态度和适度的做法.
- 在CAT使用,KAP和不服抗药 (AED) 之间没有发现显著的关联 (p > 0.05).
- 只有28.5%的CAT用户向医疗保健提供者披露了他们的使用情况.
结论:
- 在患者 (PWE) 中广泛使用CAT是由文化因素和感知到的疗效驱动的.
- 目前的发现表明,CAT使用与抗药物 (AED) 坚持之间没有直接联系.
- 建议对整合性护理模式进行进一步的研究,以确保安全和协调的管理.
相关概念视频
Drug Therapy
100
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
100
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
450
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
450
Antiepileptic Drugs: Glutamate Antagonists
516
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
516
Antiepileptic Drugs: Potassium Channel Activators
278
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
278
Electroconvulsive Therapy
189
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
189
Psychosis: Goals of Pharmacotherapy
209
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
209


